James F Chmiel

List of Publications by Citations

42 papers	3,301 citations	27 h-index	45 g-index
45 ext. papers	4,132 ext. citations	8.5 avg, IF	5.15 L-index

#	Paper	IF	Citations
42	Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *New England Journal of Medicine*, **2011**, 364, 1005-15	59.2	647
41	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *Lancet, The*, **2019**, 394, 1940-1948	40	341
40	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. *Journal of Cystic Fibrosis*, **2015**, 14, 419-30	4.1	276
39	The role of inflammation in the pathophysiology of CF lung disease. *Clinical Reviews in Allergy and Immunology*, **2002**, 23, 5-27	12.3	180
38	Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 311, 2083-91	27.4	179
37	State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. *Respiratory Research*, **2003**, 4, 8	7.3	154
36	Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 1471-5	10.2	141
35	Sputum biomarkers of inflammation in cystic fibrosis lung disease. *Proceedings of the American Thoracic Society*, **2007**, 4, 406-17		122
34	Inflammation and its genesis in cystic fibrosis. *Pediatric Pulmonology*, **2015**, 50 Suppl 40, S39-56	3.5	114
33	Airway microbiota across age and disease spectrum in cystic fibrosis. *European Respiratory Journal*, **2017**, 50,	13.6	113
32	Inflammation in cystic fibrosis: An update. *Pediatric Pulmonology*, **2018**, 53, S30-S50	3.5	106
31	Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. *Clinical Reviews in Allergy and Immunology*, **2008**, 34, 146-62	12.3	86
30	Inflammation and anti-inflammatory therapies for cystic fibrosis. *Clinics in Chest Medicine*, **2007**, 28, 331-45	3.5	78
29	Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. *Pediatric Pulmonology*, **2014**, 49, 650-8	3.5	73
28	Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1176-81	10.2	65
27	Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma. *BMC Pulmonary Medicine*, **2018**, 18, 58	3.5	54
26	Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 1177-1187	10.2	54

25	Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. *Annals of the American Thoracic Society*, **2014**, 11, 342-50	4.7	53
24	Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. *Journal of Cystic Fibrosis*, **2015**, 14, 720-6	4.1	43
23	Antibiotic and anti-inflammatory therapies for cystic fibrosis. *Cold Spring Harbor Perspectives in Medicine*, **2013**, 3, a009779	5.4	40
22	Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. *Journal of Cystic Fibrosis*, **2017**, 16, 358-366	4.1	37
21	Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2016**, 15, 227-33	4.1	35
20	Anti-inflammatory therapies for cystic fibrosis-related lung disease. *Clinical Reviews in Allergy and Immunology*, **2008**, 35, 135-53	12.3	30
19	Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. *Infection and Immunity*, **2016**, 84, 2410-21	3.7	29
18	Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. *Annals of the American Thoracic Society*, **2015**, 12, 1398-406	4.7	28
17	Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 79-93	10.2	27
16	Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. *Treatments in Respiratory Medicine*, **2005**, 4, 255-73		27
15	A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. *Journal of Cystic Fibrosis*, **2019**, 18, 708-713	4.1	25
14	Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. *Journal of Cystic Fibrosis*, **2019**, 18, 357-363	4.1	23
13	Bacterial infections in patients with primary ciliary dyskinesia: Comparison with cystic fibrosis. *Chronic Respiratory Disease*, **2017**, 14, 392-406	3	23
12	Neutrophils from F508del cystic fibrosis patients produce IL-17A and express IL-23 - dependent IL-17RC. *Clinical Immunology*, **2016**, 170, 53-60	9	23
11	Pathological Hyaluronan Matrices in Cystic Fibrosis Airways and Secretions. *American Journal of Respiratory Cell and Molecular Biology*, **2016**, 55, 576-585	5.7	16
10	Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2017**, 16, 283-290	4.1	11
9	Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial. *American Journal of Clinical Nutrition*, **2019**, 109, 544-553	7	10
8	The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis. *Contemporary Clinical Trials Communications*, **2017**, 6, 39-45	1.8	8

7	Murine models of CF airway infection and inflammation. *Methods in Molecular Medicine*, **2002**, 70, 495-515		7
6	Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 78-85	4.1	6
5	Testing the effects of combining azithromycin with inhaled tobramycin for in cystic fibrosis: a randomised, controlled clinical trial. *Thorax*, **2021**,	7.3	4
4	Geography, generalisability, and susceptibility in clinical trials. *Lancet Respiratory Medicine,the*, **2021** , 9, 330-332	35.1	3
3	Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 1934-1937.e4	11.5	1
2	Drug development for cystic fibrosis. *Pediatric Pulmonology*, **2021**, 56 Suppl 1, S10-S22	3.5	1
1	Somatic cell hemoglobin modulates nitrogen oxide metabolism in the human airway epithelium. *Scientific Reports*, **2021**, 11, 15498	4.9	0